Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site
Sebastiaan P. Prens(Erasmus MC), Cornelis Verhoef(Erasmus MC Cancer Institute), Alexander M.M. Eggermont(University Medical Center Utrecht), Albertus N. van Geel, Alexander C. J. van Akkooi(The University of Sydney), Johannes H.W. de Wilt(Radboud University Nijmegen), Augustinus P. T. van der Ploeg(Erasmus MC Cancer Institute), Cornelis A. G. M. van Montfort(Erasmus MC)
Cited by 53
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k